- Home
- LYRA
as 11-14-2025 2:33pm EST
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 7.6M | IPO Year: | 2020 |
| Target Price: | $16.00 | AVG Volume (30 days): | 30.6K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -22.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.69 - $37.50 | Next Earning Date: | 11-12-2025 |
| Revenue: | $600,000 | Revenue Growth: | -59.21% |
| Revenue Growth (this year): | -49.5% | Revenue Growth (next year): | 106.28% |
Stock Insider Trading Activity of Lyra Therapeutics Inc. (LYRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | LYRA | 10% Owner | Nov 13 '25 | Sell | $3.90 | 31,810 | $124,062.18 | 14,026 | |
| PERCEPTIVE ADVISORS LLC | LYRA | 10% Owner | Nov 12 '25 | Sell | $4.06 | 8,745 | $35,499.45 | 14,026 | |
| PERCEPTIVE ADVISORS LLC | LYRA | 10% Owner | Nov 11 '25 | Sell | $4.31 | 5,320 | $22,953.67 | 14,026 | |
| PERCEPTIVE ADVISORS LLC | LYRA | 10% Owner | Nov 10 '25 | Sell | $4.54 | 18,502 | $83,995.38 | 14,026 | |
| PERCEPTIVE ADVISORS LLC | LYRA | 10% Owner | Nov 7 '25 | Sell | $4.75 | 19,739 | $93,695.11 | 14,026 | |
| PERCEPTIVE ADVISORS LLC | LYRA | 10% Owner | Nov 6 '25 | Sell | $5.18 | 32,149 | $166,528.61 | 14,026 |
Latest Lyra Therapeutics Inc. News
LYRA Breaking Stock News: Dive into LYRA Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Zacks
11 days ago
Dentsply International (XRAY) Lags Q3 Earnings Estimates
Zacks
13 days ago
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Zacks
5 months ago
Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why
Zacks
5 months ago
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
MT Newswires
5 months ago
Top Midday Gainers
GuruFocus.com
5 months ago
Lyra Therapeutics Shares Climb Over 500% After Major CRS Trial Win
MT Newswires
5 months ago
Lyra Says Phase 3 Trial of Nasal Implant for Chronic Rhinosinusitis Meets Endpoints
Compare LYRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LYRA Lyra Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.